Compare Inovio Pharmaceuticals Inc (INO) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Lufax Holding Ltd — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Lufax Holding Ltd trades at $1.39 (market cap $2.41B). The key difference: Lufax Holding Ltd is far larger — about 27× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| INO | LU | |
|---|---|---|
Market Cap | $89.27M | $2.41B |
Sector | Health | Technology |
52-Week High | $2.87 | $4.40 |
52-Week Low | $1.05 | $1.23 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
LU trades at $1.36, down 2.16% today. The stock shows a mixed technical picture with a neutral overall signal and bearish moving averages. Fundamentally, the company reported a net loss of $2.1B on $23.1B revenue for 2025, with negative profit margins and returns. Analyst consensus is bullish with 61.5% buy ratings, but sentiment is clouded by multiple class-action lawsuits announced in May 2026 alleging securities fraud.
The outlook is cautious. While low valuation ratios (P/S 0.35, P/B 0.1) and analyst support suggest potential upside, persistent losses and significant legal overhangs pose substantial risks. Investor focus remains on the company's ability to return to profitability amid these challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
